Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
Science and technology company Merck and XtalPi, a pioneering pharmaceutical technology company powered by artificial […]
Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck
Ratio Therapeutics, a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class […]
Aqilion announces Pre-clinical Licensing and Strategic Research Collaboration Agreement with Merck
Aqilion today announced an exclusive license and strategic research collaboration with Merck to discover, develop […]
Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials
Personalis, a leader in advanced genomics for precision oncology, and Moderna, a biotechnology company pioneering […]
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
Merck, known as MSD outside of the United States and Canada, and Kelun-Biotech, a clinical-stage […]
Curve Therapeutics Announces Collaboration with MSD for Next Generation Drug Discovery Platform
Curve Therapeutics (Curve), a private biotechnology company pioneering a potentially game-changing, functional drug discovery platform, today […]
Merck KGaA, Darmstadt, Germany, Enters into Option Agreement with Quris on its BioAI Platform for Clinical Safety Prediction
Quris, an artificial intelligence (AI) innovator disrupting the pharmaceutical arena, today announced it has signed […]
Merck and Ridgeback’s Molnupiravir, an Oral COVID-19 Antiviral Medicine, Receives First Authorization in the World
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics […]
Hummingbird Bioscience to Collaborate with Merck on Clinical Trial of Anti-VISTA Antibody HMBD-002 in Combination with KEYTRUDA® (Pembrolizumab) for Treatment of Cancer
Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more